Brilacidin is not their main hope, it is just the one that should come to fruition sooner than Kevetrin or Prurisol. It's the one that will allow them to keep the lion's share of the partnerships, when they come to be, for both Kevetrin and Prurisol. The fact that they are pointing out that Brilacidin is much more commercial than first thought, why it was overlooked by other pharmas, and why this allowed CTIX to basically steal PolyMedix from under the noses of the biotech elders is an extremely positive statement for mgt in my book and this harping on their "fluff" PR's I find total BS. I look at it more as a "Rubbing it in your face" type of PR rather than "fluff" and it certainly sends a shot across the bow to whomever wants to partner with us regarding Brilacidin that it is not going to come cheap.
I thought today was another extremely strong step for CTIX and I expect to see them continue throughout this year.
Well done, Leo, from at least one backer!
News 
Market Data 
Discover 
